Moffitt Cancer Center Logo
 

Julio M. Pow-Sang, MD

Where You Are:
Julio M. Pow-Sang, MD

Senior Member

Office  (813) 745-8418

Education And Training
  • MBA, University of South Florida, 1997
  • Fellow, University of Florida College of Medicine, 1987 - Urologic Oncology
  • Resident, University of Miami School of Medicine, 1986 - Urology
  • Resident, University of Miami School of Medicine, 1983 - General Surgery
  • MD, University Autonoma De Guadalajara, Mexico, 1981


Dr. Pow-Sang’s research interests focus on molecular markers for prostate cancer behavior.

  • Espiritu PN, Sverrisson EF, Sexton WJ, Pow-Sang JM, Poch MA, Dhillon J, Spiess PE. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection. Urol Oncol. 2014 Feb. Pubmedid: 24495448.
  • Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE. Surgical Outcomes in the Management of Isolated Nodal Recurrences: A Multicenter International Retrospective Cohort. J Urology. 2014 Feb. Pubmedid: 24530987.
  • Sverrisson EF, Nguyen H, Kim T, Pow-Sang JM. Primary cryosurgery for clinically localized prostate cancer--do perioperative tumor characteristics correlate with post-treatment biopsy results?. Urology. 2014 Feb;83(2):376-378. Pubmedid: 24315311.
  • Chornokur G, Amankwah EK, Davis SN, Phelan CM, Park JY, Pow-Sang J, Kumar NB. Variation in HNF1B and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study. Prostate Cancer. 2014 Jan;2013:384594. Pubmedid: 24386569. Pmcid: PMC3872424.
  • Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M. Prostate cancer, version 1.2014. J Natl Compr Canc Ne. 2013 Dec;11(12):1471-1479. Pubmedid: 24335682.
  • Nguyen HD, Allen BJ, Pow-Sang JM. Focal cryotherapy in the treatment of localized prostate cancer. Cancer Control. 2013 Jul;20(3):177-180. Pubmedid: 23811701.
  • Sverrisson E, Jones JS, Pow-Sang JM. Cryosurgery for prostate cancer: a comprehensive review. Arch Esp Urol. 2013 Jul;66(6):546-556. Pubmedid: 23985454.
  • Pow-Sang JM. The improving landscape of urologic oncology. Cancer Control. 2013 Jul;20(3):158-159. Pubmedid: 23811699.
  • Chornokur G, Han G, Tanner R, Lin HY, Green BL, Pow-Sang J, Phelan CM. High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: results from a pilot study. Cancer Lett. 2013 May;331(2):154-157. Pubmedid: 23268329. Pmcid: PMC3603576.
  • Amankwah EK, Anegbe E, Park H, Pow-Sang J, Hakam A, Park JY. miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases. Asian J Androl. 2013 Mar;15(2):226-230. Pubmedid: 23353719. Pmcid: PMC3705740.
  • Spiess PE, Kurian T, Lin HY, Rawal B, Kim T, Sexton WJ, Pow-Sang JM. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. BJU Int. 2012 Dec;110(11 pt B):E470-E474. Pubmedid: 22519938.
  • Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM, Dickinson SI, Lin HY, Spiess PE. Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2012 Dec;110(11 pt B):E475-E480. Pubmedid: 22564727.
  • Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Sep;10(9):1081-1087. Pubmedid: 22956807.
  • Buethe DD, Pow-Sang J. Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer. J Natl Compr Canc Netw. 2012 Sep;10(9):1101-1110. Pubmedid: 22956809.
  • Rivers BM, August EM, Quinn GP, Gwede CK, Pow-Sang JM, Green BL, Jacobsen PB. Understanding the Psychosocial Issues of African American Couples Surviving Prostate Cancer. J Cancer Educ. 2012 Jun;27(3):546-558. Pubmedid: 22544536.
  • Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, Kang L, Chuang T, Seigne J, Pow-Sang J, Torres-Roca JF, Heysek R, Biagoli M, Shankar R, Scott J, Antonia S, Gabrilovich D, Fishman M. Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy. 2012 Apr;4(4):373-382. Pubmedid: 22512631.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar;33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
  • Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan;2(1). Pubmedid: 24533253. Pmcid: PMC3924733.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W. Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther. 2012 Jan;2011(S3). Pubmedid: 22422102.
  • Lin HY, Park HY, Radlein S, Mahajan NP, Sellers TA, Zachariah B, Pow-Sang J, Coppola D, Ganapathy V, Park JY. Protein expressions and genetic variations of SLC5A8 in prostate cancer risk and aggressiveness. Urology. 2011 Oct;78(4):971.e1-971.e9. Pubmedid: 21802122. Pmcid: PMC3190039.
  • Ercole CE, Pow-Sang JM, Spiess PE. Update in the surgical principles and therapeutic outcomes of inguinal lymph node dissection for penile cancer. Urol Oncol. 2011 Apr;31(5):505-516. Pubmedid: 21481617.
  • Pow-Sang JM. Editorial comment. Urology. 2011 Feb;77(2):367. Pubmedid: 21295251.
  • Rivers BM, August EM, Gwede CK, Hart A, Donovan KA, Pow-Sang JM, Quinn GP. Psychosocial issues related to sexual functioning among African-American prostate cancer survivors and their spouses. Psychooncology. 2011 Jan;20(1):106-110. Pubmedid: 20187071.
  • Kolla SB, Ercole C, Spiess PE, Pow-Sang JM, Sexton WJ. Nephron-sparing surgery for pathological stage T3b renal cell carcinoma confined to the renal vein. BJU Int. 2010 Nov;106(10):1494-1498. Pubmedid: 20230378.
  • Correa JJ, Pow-Sang JM. Optimizing cancer control and functional outcomes following robotic prostatectomy. Cancer Control. 2010 Oct;17(4):233-244. Pubmedid: 20861811.
  • Pow-Sang JM. Progress in treatment of genitourinary malignancies. Cancer Control. 2010 Oct;17(4):212. Pubmedid: 20861808.
  • Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb;8(2):162-200. Pubmedid: 20141676.
  • Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009 Nov;27(5):496-501. Pubmedid: 18639470. Pmcid: PMC2743955.
  • Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G, Easton DF. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009 Oct;41(10):1116-1121. Pubmedid: 19767753. Pmcid: PMC2846760.
  • Caso J, Seigne J, Back M, Spiess PE, Pow-Sang J, Sexton WJ. Circumferential resection of the inferior vena cava for primary and recurrent malignant tumors. J Urol. 2009 Sep;182(3):887-893. Pubmedid: 19616230.
  • Coppola D, Oliveri C, Sayegh Z, Boulware D, Takahashi Y, Pow-Sang J, Djeu JY, Wang HG. Bax-interacting factor-1 expression in prostate cancer. Clin Genitourin Cancer. 2008 Sep;6(2):117-121. Pubmedid: 18824435. Pmcid: PMC2626142.
  • Fishman M, Hunter T, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo M, Noyes D, Mahany J, Lee J, Cantor A, Messina J, Seigne J, Pow-Sang J, JanssenW, Antonia S. Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma. J Immunother (1997). 2008 Jan;31(1):72-80. Pubmedid: 18157014.
  • Pow-Sang J. Pure and robotic-assisted laparoscopic radical prostatectomy: technology and techniques merge to improve outcomes. Expert Rev Anticancer Ther. 2008 Jan;8(1):15-19. Pubmedid: 18095879.
  • Park J, Zheng W, Kim D, Cheng J, Kumar N, Ahmad N, Pow-Sang J. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2007 Nov;31(5):359-365. Pubmedid: 18037591.
  • Barnholtz-Sloan J, Maldonado J, Pow-Sang J, Giuliano A. Incidence trends in primary malignant penile cancer. Urol Oncol. 2007 Sep;25(5):361-367. Pubmedid: 17826651.
  • Park J, Tanner J, Sellers T, Huang Y, Stevens C, Dossett N, Shankar R, Zachariah B, Heysek R, Pow-Sang J. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology. 2007 Aug;70(2):374-379. Pubmedid: 17826523.
  • Mohler J, Babaian R, Bahnson R, Boston B, D'Amico A, Eastham J, Hauke R, Huben R, Kantoff P, Kawachi M, Kuettel M, Lange P, Logothetis C, MacVicar G, Pollack A, Pow-Sang J, Roach M 3rd, Sandler H, Shrieve D, Srinivas S, TwardowskiP, Urban D, Walsh P. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug;5(7):650-683. Pubmedid: 17692170.
  • Correa J, Politis C, Rodriguez A, Pow-Sang J. Laparoscopic retroperitoneal lymph node dissection in the management of testis cancer. Cancer Control. 2007 Jul;14(3):258-264. Pubmedid: 17615532.
  • Pow-Sang J, Velasquez J, Myers M, Rodriguez A, Kang L. Pure laparoscopic and robotic-assisted laparoscopic radical prostatectomy in the management of prostate cancer. Cancer Control. 2007 Jul;14(3):250-257. Pubmedid: 17615531.
  • Rodriguez A, Kapoor R, Pow-Sang J. Laparoscopic extraperitoneal radical prostatectomy in complex surgical cases. J Urol. 2007 May;177(5):1765-1770. Pubmedid: 17437812.
  • Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 2007;59(2):163-168. Pubmedid: 18001210. Pmcid: PMC2435485.
  • Kumar NBB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer. 2007;59(2):169-175. Pubmedid: 18001211. Pmcid: PMC2442460.
  • Patterson S, Wei S, Chen X, Sallman D, Gilvary D, Zhong B, Pow-Sang J, Yeatman T, Djeu J. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene. 2006 Nov;25(45):6113-6122. Pubmedid: 16652143.
  • Torres-Roca J, Cantor A, Shukla S, Montejo M, Friedland J, Seigne J, Heysek R, Pow-Sang J. Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience. Urol Oncol. 2006 Oct;24(5):384-390. Pubmedid: 16962486.
  • Rodriguez A, Pow-Sang J. Laparoscopic surgery in urologic oncology. Cancer Control. 2006 Jul;13(3):169-178. Pubmedid: 16885912.
  • Rodriguez A, Kang L, Politis C, Wade M, Sexton W, Miranda-Sousa A, Pow-Sang JM. Delayed metastatic renal carcinoma to prostate. Urology. 2006 Mar;67(3):623-623. Pubmedid: 16527593.
  • Chen L, Ambrosone CB, Lee J, Sellers TA, Pow-Sang J, Park JY. Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol. 2006 Jan;175(1):108-112. Pubmedid: 16406883.
  • Pow-Sang J. Uro-oncology: improved techniques produce better outcomes. Cancer Control. 2006;13(3):156-156. Pubmedid: 16885910.
  • Gwede C, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K, Cantor A, Jacobsen P. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer. 2005 Oct;104(7):1381-1390. Pubmedid: 16080181.
  • Rodriguez A, Burday D, Sexton W, Ahmad N, Pow-Sang J. Urothelial carcinoma in a child. Arch Esp Urol. 2005 Jun;58(5):473-475. Pubmedid: 16078794.
  • Kumar N, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004 May;59(2):141-147. Pubmedid: 15042614.
  • Jacobsen P, Lamonde L, Honour M, Kash K, Hudson P, Pow-Sang J. Relation of family history of prostate cancer to perceived vulnerability and screening behavior. Psychooncology. 2004;13(2):80-85. Pubmedid: 14872526.
  • Vadaparampil S, Jacobsen P, Kash K, Watson I, Saloup R, Pow-Sang J. Factors predicting prostate specific antigen testing among first-degree relatives of prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 2004;13(5):753-758. Pubmedid: 15159306.
  • Park J, Chen L, Shade K, Lazarus P, Seigne J, Patterson S, Helal M, Pow-Sang J. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol. 2004;171(6Pt1):2484-2488. Pubmedid: 15126881.
  • Pow-Sang J. Genitourinary oncology: the continuous evolution of multimodality treatments. Cancer Control. 2004;11(6):351-351. Pubmedid: 15625521.
  • Moreira S, Seigne J, Ordorica R, Marcet J, Pow-Sang J, Lockhart J. Devastating complications after brachytherapy in the treatment of prostate adenocarcinoma. Bju Int. 2004;93(1):31-35. Pubmedid: 14678363.
  • Keehn C, Pow-Sang J, Ahmad N. Pathologic quiz case: a 57-year-old man with hypertension and hypokalemia. Arch Pathol Lab Med. 2003 Apr;127(4):495-496. Pubmedid: 12683884.
  • Shukla A, Pow-Sang J, Helal M, Seigne J, Ordorica R, Lockhart J. Urinary incontinence after continent urinary diversion using cecal wrap or plicated ileum: a patient questionnaire review. Urology. 2003;61(2):328-331. Pubmedid: 12597940.
  • Webster C, Bukkapatnam R, Seigne J, Pow-Sang J, Hoffman M, Helal M, Ordorica R, Lockhart J. Continent colonic urinary reservoir (Florida pouch): long-term surgical complications (greater than 11 years). J Urol. 2003;169(1):174-176. Pubmedid: 12478129.
  • Chen L, Elahi A, Pow-Sang J, Lazarus P, Park J. Association between polymorphism of human oxoguanine glycosylase 1 (hOGG1) and risk for prostate cancer. J Urol. 2003;170(6 Pt1):2471-2474. Pubmedid: 14634453.
  • Thurman S, Robinson L, Ahmad N, Pow-Sang J, Lockhart J, Seigne J. Investigation of the safety and accuracy of intraoperative gamma probe directed biopsy of bone scan detected rib abnormalities in prostatic adenocarcinoma. J Urol. 2003;169(4):1341-1344. Pubmedid: 12629356.
  • Mora L, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, FalconeR, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62(22):6659-6666. Pubmedid: 12438264.
  • Patterson S, Balducci L, Pow-Sang J. Controversies surrounding androgen deprivation for prostate cancer. Cancer Control. 2002;9(4):315-325. Pubmedid: 12228757.
  • Moreira SG J, Pow-Sang J. Evaluation and management of adrenal masses. Cancer Control. 2002;9(4):326-334. Pubmedid: 12228758.
  • Antonia S, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo M, Friberg M, Alsarraj M, Mahany J, Pow-Sang J, Cantor A, Janssen W. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002;167(5):1995-2000. Pubmedid: 11956426.
  • Pow-Sang M, Benavente V, Pow-Sang J, Morante C, Meza L, Baker M, Pow-Sang JM. Cancer of the penis. Cancer Control. 2002;9(4):305-314. Pubmedid: 12228756.
  • Pow-Sang J. The spectrum of genitourinary malignancies. Cancer Control. 2002;9(4):275-276. Pubmedid: 12228752.
  • Pow-Sang J. Prostate cancer at the beginning of the 21st century: more options and better outcomes. Cancer Control. 2001 Nov;8(6):480-481. Pubmedid: 11807417.
  • Bukkapatnam R, Pow-Sang J. Radical prostatectomy in the management of clinically localized prostate cancer. Cancer Control. 2001;8(6):496-502. Pubmedid: 11807419.
  • Hoff B, Pow-Sang J. Observation in the management of localized prostate cancer. Cancer Control. 2001;8(2):151-154. Pubmedid: 11326169.
  • Pow-Sang J. Clinically localized prostate cancer: the paradox of paradoxes. Cancer Control. 2001;8(2):126-126. Pubmedid: 11326166.
  • Pow-Sang J. Bladder cancer: one enemy, many fronts. Cancer Control. 2000 Jul;7(4):307-307. Pubmedid: 10895125.
  • Diaz J, Pow-Sang J, Mora L, Seigne J, Cantor A, Dalton W. Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol. 2000;5(4):149-154. Pubmedid: 10869956.
  • Pow-Sang J. The best readings on genitourinary tumors. (Editorial). Cancer Control. 1999;6(6):594-595. Pubmedid: noPMID.
  • Chabarek N, Mora L, Diaz J, Pow-Sang J. La edad como factor de riesgo de complicaciones post-operatorias en prostatectomia radical retropubica. Urologia Panamericana. 1999;11(3):17-19. Pubmedid: noPMID.
  • Pow-Sang J. Just the facts, ma'am. Cancer Control. 1999;6(6):545-546. Pubmedid: 10756385.
  • Masel J, Austin P, Spyropoulos E, Seigne J, Pow-Sang J, Odorica R, Lockhart J. Enterocystometric comparison of plicated ileocecal segment (PI) and flap valve (IV) continence mechanisms in the Florida pouch. Urology. 1999;53(3):506-509. Pubmedid: 10096375.
  • Diaz J, Mora L, Austin P, Muro-Cacho C, Cantor A, Nicosia S, Pow-Sang J. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology. 1999;53(5):931-938. Pubmedid: 10223486.
  • Pow-Sang J, Friedland J, Seigne J, Feygelman V. Brachytherapy for prostate cancer. Urologia Panamericana. 1999;11(4):24-26. Pubmedid: noPMID.
  • Seigne J, Turner J, Diaz J, Hackney J, Pow-Sang J, Helal M, Lockhart J, Yu H. A feasiblity study of gene gun mediated immunotherapy for renal cell carcinoma. J Urol. 1999;162(4):1259-1263. Pubmedid: 10492175.
  • Feygelman V, Pow-Sang J, Friedland J, Sanders R. Needle imaging during ultrasound-guided permanent prostate implants. Tech Urol. 1999;3:143-145. Pubmedid: noPMID.
  • Lynch C, Towsley G, Pow-Sang J, Lockhart J, Seigne J. Long-term urodynamic changes of a continent colonic urinary reservoir. J Pelvic Surgeons. 1999;5(1):13-16. Pubmedid: noPMID.
  • Mora L, Moscinski L, Diaz J, Blair P, Cantor A, Pow-Sang J. Stage B prostate cancer: correlation of DNA ploidy analysis with histological and clinical parameters. Cancer Control. 1999;6(6):587-591. Pubmedid: 10756390.
  • Benson K, Agosti S, Lyman G, Pow-Sang J, Saba H, Balducci L. Estimated blood loss in group O as compared to non-group O radical prostatectomy. Hematology. 1998;3:257-261. Pubmedid: noPMID.
  • Pow-Sang J. Prostate cancer: of turtles, birds, and rabbits. Cancer Control. 1998;5(6):483-484. Pubmedid: 10761096.
  • Lynch C, Towsley G, Pow-Sang J, Lockhart J. Long-term urodynamic evaluation of a continent urinary reservoir. Prim Care Update Ob Gyns. 1998;5(4):200-200. Pubmedid: 10838382.
  • Pow-Sang J. Ten best readings on prostate cancer. Cancer Control. 1998;5(6):559-560. Pubmedid: noPMID.
  • Benson K, Lyman G, Agosti S, Balducci L, Pow-Sang J, Saba H. 1997;127a.
  • Helal M, Austin P, Spyropoulos E, Pow-Sang J, Persky L, Lockhart J. Evaluation and management of parastomal hernia in association with continent urinary diversion. J Urol. 1997;157:1630-1632. Pubmedid: 9112492.
  • Pow-Sang J. Genitourinary cancers:update on detection, treatment, and research. Cancer Control. 1996;6(3):486-487.
  • Diaz J, Nicosia S, Szakacs J, Pow-Sang J, Saba H. Metastatic Seminoma Simulating Malignant lymphoma in an HIV infected hemophiliac. Leuk Lymphoma. 1996;23:165-171. Pubmedid: 9021701.
  • Pow-Sang J, Spyropoulos E, Helal M, Lockhart J. Bladder replacement and urinary diversion after radical cystectomy. Cancer Control. 1996;3(6):512-518. Pubmedid: 10764510.
  • Rabb H, Borrasa E, Adams R, Pow-Sang J, Ramirez G. Alpha-v/beta-3 and alpha-5/beta-3 integrin expression in cancerous kidney. Am J Nephrol. 1996;16:402-402. Pubmedid: 8886177.
  • Pow-Sang J. Ten best readings. Cancer Control. 1996;3(3):542-543.
  • Pow-Sang J, Marshburn J. Prostate cancer clinical guidelines. Cancer Control. 1996;6(3):526-627. Pubmedid: 10764513.
  • Mora L, Nicosia S, Pow-Sang J, Ku N, Diaz J, Lockhart J, Einstein, Jr. A. Ancillary techniques in the follow-up of trasitional cell carcinoma: a comparision of cytology, histology and DNA image analysis cytometry in 91 patients. J Urol. 1996;156:49-55. Pubmedid: 8648836.
  • Helal M, Figueroa T, Pow-Sang J, Sanford E, Lockhart J. A trans-reservoir technique for correction of ureterointestinal obstruction in continenta urinary diversion. J Urol. 1995;153:1108-1109. Pubmedid: 7869474.
  • Pow-Sang J. Carta del editor invitado. Urologia Panamericana. 1995;7:1-2. Pubmedid: noPMID.
  • Pow-Sang J. Contoversias en el manejo de cancer de rinon. Urologia Panamericana. 1995;7:41-46. Pubmedid: noPMID.
  • Horton J, Pow-Sang J. Continuing medical education. Cancer Control. 1995;2(1):77-81. Pubmedid: noPMID.
  • Diaz J, Nicosia S, Szakacs J, Pow-Sang J, Saba H. Metastatic seminoma simulating malignant lymphoma in an HIV infected hemophiliac. Leuk Lymphoma. 1995;18:179-184. Pubmedid: noPMID.
  • Friedland J, Pow-Sang J, Johnson D, Byrnes J. Quality of life issues associated with the treatment of prostate cancer. Cancer Control. 1995;2(1):42-46. Pubmedid: 10887396.
  • Pow-Sang J. Prostate cancer: detection and management. Cancer Control. 1995;1(2):9-9. Pubmedid: 10887390.
  • Pow-Sang J. Ten best readings in prostate cancer. Cancer Control. 1995;1(2):62-63. Pubmedid: noPMID.
  • Greene J, Sandin R, Fields K, Moscinski L, Beatty A, Pow-Sang J, Elfenbein G. Hemorrhagic cystitis in bone marrow transplant patients: is it an infection or chemotherapy toxicity?. Cancer Control. 1994;1(4):411-415.
  • Szakacs J, Pow-Sang J. The pathologist's role in multidisciplinary management of bladder cancer. Ann Clin Lab Sc. 1994;24(6):481-488.
  • Katz M, Sanford E, Valle J, Lowe D, Pow-Sang J, Braman R. 1993;240A.
  • Gray G, Hernandez O, Hebel D, Root M, Pow-Sang J. Antisense DNA inhibition of HA-RAS induced tumor growth in nude mice. Cancer Res. 1993;53:577-580.
  • Helal M, Pow-Sang J, Sanford E, Figueroa T, Lockhart J. Direct (non-tunnelled) uretero-colonic reimplantation in association with continent reservoirs. J Urol. 1993;150:835-837.
  • Shabaik A, Pow-Sang J, Lockhart J, Nicosia S. Role of DNA image cytometry in the follow-up of patients with urinary tract transitional cell carcinoma. Acta Cytol. 1993;15(2):115-123. Pubmedid: 8318126.
  • Pow-Sang J, Helal M, Figueroa E, Sanford E, Persky L, Lockhart J. Conversion from external appliance wearing or internal urinary diversion to a continent urinary reservoir (Florida pouch I and II): surgical technique, indications and complications. J Urol. 1992;147:356-360.
  • Pow-Sang J, Lockhart J, Helal M, Persky L, Sanford E. The Florida pouch: diversion to minimize obstruction. Contemp Urol. 1992;4(2):20-29.
  • Pow-Sang J, Lockhart J. Continent urinary diversion: the Florida pouch. Problems In Urology. 1992;6(3):581-586.
  • Lockhart J, Pow-Sang J, Persky L, Sanford E. The Florida pouch: a simplified technique for continent urinary diversion. Urologia Panamericana. 1990;2(1):33-39.
  • Lockhart J, Pow-Sang J, Persky L, Kahn P, Vorstman B, Ellis G, Helal M. Detivacao urinaria continente desenvolvida na Florida: uma te cnica para a America Latina. J Bras Urol. 1989;15:115-115.
  • Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Besterman-Dahan K, Krischer JP. Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol. 2010 Winter;8(1):3-13. Pubmedid: 20205984.
  • Pow-Sang J, Pow-Sang J. Tratado De Urologia Oncologica. 1997.
  • Heysek R, Gwede C, Torres-Roca J, Cantor A, Kelley S, Saini A, Pow-Sang J. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy. 5(4):244-250. Pubmedid: 17118318.
  • Balducci L, Pow-Sang J, Friedland J, Diaz J. Cancer in the elderly part II: prostate cancer. In: Balducci L, ed. Clinics in geriatric medicine. Philadelphia, PA: Saunders; 1997;283-306.
  • Feygelman V, Friedland J, Sanders R, Noriega B, Pow-Sang J. Improvement in dosimetry of ultrasound-guided prostate implants with the use of multiple stabilization needles. Med Dosim. 1996 Sum;21(2):109-112. Pubmedid: 8807612 .
  • Torres-Roca JF, Cantor AB, Shukla S, Montejo ME, Friedland J, Seigne JD, Heysek R, Heysek, Randy, Pow-Sang J. Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience. Urol Oncol. 2006 Sept - Oct;24(5):384-390.
  • Pow-Sang J, Seigne J. Contemporary management of superficial bladder cancer. Cancer Control. 7(4):335-339. Pubmedid: 10895127.
  • Pow-Sang J, Pow-Sang J. Manual De Urologia, Primera Edicion. Lima, Peru. Editorial Piramide; 1996.
  • Pow-Sang J, Friedland J, Einstein, Jr. A. Transitional carcinoma of the bladder in the elderly. In: Comprehensive Geriatric Oncology. London. Harwood Academic Publishers; 1998;697-702.
  • Rodriguez AR, Rachna K, Pow-Sang JM. Laparoscopic extraperitoneal radical prostatectomy: impact of the learning curve on perioperative outcomes and margin status. JSLS. 14(1):6-13. Pubmedid: 20529523. Pmcid: PMC3021300.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer